Final Overall Survival Analysis of MONARCH 2: A Phase 3 Trial of Abemaciclib plus Fulvestrant in Patients with Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer | Publicación